Chordoma: the entity

Area of Science:

• Oncology
• Molecular Biology
• Skeletal Pathologies

Background:

• Chordomas are malignant tumors originating from the axial skeleton.
• They are characterized by slow, aggressive local invasion, often affecting the skull base and sacrum.
• Patients experience debilitating neurological symptoms, with a 5-year survival rate of 65%.

Purpose of the Study:

• To provide an overview of current chordoma treatment paradigms.
• To summarize recent research findings on chordoma development.
• To highlight novel molecular discoveries in chordoma.

Main Methods:

• Review of existing literature on chordoma.
• Analysis of molecular events contributing to chordoma pathogenesis.
• Synthesis of current treatment strategies and outcomes.

Main Results:

• Chordomas are resistant to conventional chemotherapy.
• Surgical resection and adjuvant radiotherapy are primary treatments.
• Recurrent disease is a common challenge in chordoma management.

Conclusions:

• Understanding molecular alterations is key to advancing chordoma treatment.
• The identification of brachyury is a significant recent finding.
• Continued research into chordoma pathogenesis offers promising therapeutic avenues.